Back to Search
Start Over
Controversies on chemotherapy for early HR+/HER2- breast cancer: the role of anthracyclines and dose intensification.
- Source :
-
Current opinion in oncology [Curr Opin Oncol] 2024 Nov 01; Vol. 36 (6), pp. 495-502. Date of Electronic Publication: 2024 Jun 12. - Publication Year :
- 2024
-
Abstract
- Purpose of Review: Use of adjuvant chemotherapy significantly reduces the risk of recurrence and improves overall survival (OS) in patients with early-stage breast cancer. However, few data are available on the efficacy of different adjuvant chemotherapy regimens and schedules in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. We aim to summarize the available evidence on the efficacy of adjuvant anthracycline-based chemotherapy and of the dose-dense schedule in this specific patient population. Moreover, current controversies in the management of patients with early-stage HR+/HER2- breast cancer are discussed.<br />Recent Findings: Patient-level meta-analysis evaluating the role of the addition of an anthracycline to taxane-based chemotherapy showed that recurrence rate was lower among patients receiving anthracycline-based treatment.Patient-level meta-analysis evaluating the role of different schedules of chemotherapy administration showed that the use of adjuvant dose-dense chemotherapy is associated with significant reduction in breast cancer recurrences and breast cancer mortality. Less evidence is available in the neoadjuvant setting.<br />Summary: For patients with high-risk HR+/HER2- breast cancer, (neo) adjuvant anthracycline and taxane-based chemotherapy, and a dose-dense regimen should still be considered the standard of care. However, in patients with intermediate risk breast cancer candidates to chemotherapy, anthracycline-free regimens could be considered the preferred treatment option.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Humans
Female
Chemotherapy, Adjuvant
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Receptors, Estrogen metabolism
Receptors, Progesterone metabolism
Breast Neoplasms drug therapy
Breast Neoplasms metabolism
Anthracyclines administration & dosage
Anthracyclines therapeutic use
Receptor, ErbB-2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1531-703X
- Volume :
- 36
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current opinion in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 39011733
- Full Text :
- https://doi.org/10.1097/CCO.0000000000001062